Roche opens French R&D center; BioMarin to create 100 jobs with $48.5 Irish plant purchase;

@FierceBiotech: Sen. Brown accuses an arbitrary FDA of "crushing" biotechs. News | Follow @FierceBiotech

> Roche has opened a new R&D center in France to build strategic research partnerships in the country focusing on translational medicine. News

> BioMarin will purchase Pfizer's Cork, Ireland manufacturing plant for $48.5 million. The acquisition is expected to create 100 jobs over the next five years at the facility. BioMarin release

> Jubilant Biosys and AstraZeneca have hit another milestone in their pain drug discovery pact. The companies' agreement now extends into cardiovascular and metabolic diseases. Jubilant release

> Arno Therapeutics' Phase II study of AR-67, a glioblastoma treatment, has hit its mid-stage target goals. The study is focusing on patients who have not previously been treated with Avastin. Item

Pharma News

@FiercePharma: AZ announces $1.8B dental-unit sale. Article | Follow @FiercePharma

> Pfizer/BMS data poses threat to BI's Pradaxa. News

> AZ chief calls on U.S. to slash taxes. Report

Vaccines News

> ImmunoCellular gains brain cancer vax patent. Article

> Protein could lead to better TB vaccine. News

> Univ of Leeds cancer vax approach shows promise in study. Story

> Researchers target weakness in HIV protein. Item

Manufacturing News

> Vax maker CSL hit with FDA warning. Article

> ICH hits milestone: Q11 draft posted for comments. Item

> Masked informant leads fakes raid in Nigeria. News

> Abbott diabetes gear lost in cargo theft. Article

> Lonza adds early-phase bio-production service. Report

> Abbott delays pink slips due to product demand. Story

And Finally... If you're a teenager or texting lover, Botox may inhibit your ability to let your fingers fly. After receiving Botox treatment for hyperhidrosis (excessive sweating), one teenager suffered from hand muscle weakness, which limited her texting for about six weeks. Story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.